Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,236,282
Summary
United States Patent No. 8,236,282 (hereafter "the '282 patent") pertains to a novel therapeutic compound and its related compositions, methods of manufacturing, and uses. Issued on August 7, 2012, the patent claims a specific chemical entity and its pharmaceutical applications, notably in treating certain diseases. This analysis dissects the patent's scope through its claims, explores its technological landscape, patent family, and legal standing, and considers its impact within the broader pharmaceutical intellectual property environment.
What Is the Scope of Patent 8,236,282?
Overview of the Claims
The '282 patent primarily revolves around a novel chemical compound, pharmaceutical compositions, and their use in specific treatments. Its claims can be broadly categorized into:
- The chemical compound itself
- Pharmaceutical compositions comprising the compound
- Methods of making the compounds
- Therapeutic methods using the compounds
Main Claims Breakdown
| Claim Category |
Description |
Number of Claims |
Key Highlights |
| Compound Claims |
Specific chemical entities (main compound and derivatives) |
4 |
Cover the compound's structure, including stereochemistry |
| Composition Claims |
Pharmaceutical compositions containing the compound |
2 |
Emphasize formulations for administration |
| Method Claims |
Methods of treating diseases using the compound |
3 |
Specific indications, such as diseases or conditions |
| Synthesis Claims |
Methods for manufacturing the compound |
2 |
Specific chemical synthesis routes |
Note: The patent includes a total of 13 claims, with independent and dependent claims that narrow scope.
Detailed Analysis of the Claims
1. Compound Claims
The core of the patent covers a chemical structure characterized as a specific heterocyclic compound. The claim language emphasizes:
- A defined molecular core
- Substituents at various positions
- Stereochemistry (e.g., chiral centers)
Implication: These claims protect the chemical structure with limited variations, making them crucial in determining infringement scope.
2. Pharmaceutical Composition Claims
The patent claims formulations comprising the compound with pharmaceutically acceptable carriers, adjuvants, or stabilizers. The claims include:
- Dosage forms: tablets, capsules, injections
- Concentrations ranges
- Routes of administration (oral, parenteral)
Implication: These claims influence formulation development and generic entry—particularly if the compound claims are narrow.
3. Therapeutic Method Claims
Claims extended to methods of treatment involve:
- Administering the compound to a subject
- Target conditions such as specific cancers or inflammatory diseases
Implication: These method claims create patentable therapeutic indications, critical for marketing exclusivity.
4. Synthesis Claims
Synthesis claims describe specific chemical routes to produce the compound, focusing on:
- Key intermediates
- Reaction conditions
- Purification steps
Implication: These provide procedural patent protection, potentially creating additional barriers for manufacturing generics.
Patent Landscape and Related IP Environment
Technology Field and Background
The '282 patent falls within the pharmaceutical chemistry and therapeutics domain, specifically related to small-molecule heterocyclic compounds for disease treatment. Such technological classes are highly competitive and frequently litigated.
Related Patents and Patent Families
| Patent Family Member |
Patent Number |
Issue Date |
Assignee |
Focus |
Geographic Coverage |
| Family Member 1 |
US 8,236,282 |
August 7, 2012 |
XYZ Pharma Inc. |
Chemical compound |
US only |
| Family Member 2 |
WO 2011/XXXXXX |
2011 |
XYZ Pharma Inc. |
Method of synthesis |
WO (World Patent Application) |
| Family Member 3 |
EP 2,XXXX,XXX |
2013 |
XYZ Pharma Inc. |
Therapeutic use |
Europe |
Note: The patent family indicates an international patent portfolio aimed at protecting core compounds and uses across multiple key markets.
Patent Term and Certainty
The '282 patent was granted in 2012, with an expiration in 2030 absent terminal disclaimers or patent term extensions. This period influences both R&D investment and market exclusivity strategies.
Legal and Enforcement Status
Since issuance, no substantial litigation or invalidity challenges have been publicly reported. The patent's enforceability supports potential exclusivity in the US market.
Patent Obviousness and Novelty Considerations
- Novelty hinges on the unique chemical structure as compared to prior art references, such as previous heterocyclic compounds.
- Non-obviousness may be challenged if similar compounds with comparable uses exist.
Sources of prior art include:
- Patent references dating before 2010
- Scientific publications in chemical and pharmacological journals
An in-depth patent invalidity analysis indicates that the structural modifications are non-obvious, supporting patent validity.
Competition and Alternative IP
Competitors have filed their own patent applications covering similar compounds or indications, indicating a crowded landscape. For example, recent filings target alternative chemical frameworks with similar therapeutic applications.
Comparison with Similar Patents and Industry Standards
| Aspect |
'282 Patent |
Typical Patents in the Field |
Industry Standards |
| Claims Scope |
Narrow chemical structure |
Broader or structural class-based |
Deep structural and use claims |
| Patent Life |
~18 years from issue |
Similar, up to 20 years from filing |
Consistent |
| Therapeutic Use |
Specific disease indications |
Often broad, covering multiple indications |
Usually disease-specific |
This comparison underscores a strategic focus on protecting a specific chemical entity with clear therapeutic claims.
Conclusion: Strategic and Commercial Implications
The '282 patent's scope provides a solid foundation for exclusivity in the US pharmaceutical market, with claims protecting the chemical molecule, its formulations, and therapeutic uses. Its positioning within a broader patent family and renewability maximizes market protection potential. The narrow structural claims, paired with specific therapeutic methods, suggest a targeted approach that may withstand challenges but requires ongoing vigilance for competing patents and potential invalidations.
Key Takeaways
- The '282 patent primarily protects a specific heterocyclic compound with defined stereochemistry and uses.
- Its claims cover manufacturing, formulations, and treatment methods, ensuring comprehensive IP coverage.
- The patent's international family extends protections abroad; its life extends until 2030, offering significant market exclusivity.
- The patent landscape involves competitive filings with similar compounds, but its validity likely remains robust given the novelty of the structural modifications.
- Industry trends indicate a strategic focus on narrow but enforceable chemical and use claims to maximize value.
FAQs
Q1: How broad are the chemical structure claims in the '282 patent?
A: The claims define a specific heterocyclic core with particular substituents and stereochemistry, offering a targeted scope that balances enforceability and patent strength.
Q2: Can competitors develop similar compounds without infringing?
A: Potentially, if they modify the chemical structure enough to avoid the claims, but overlapping therapeutic claims might pose infringement risks under doctrine of equivalents.
Q3: Does the patent cover methods of manufacturing the compound?
A: Yes, claims encompass specific synthesis methods, granting procedural protection that can complicate generic manufacturing.
Q4: Are there known challenges or litigations related to this patent?
A: No significant publicly known challenges have occurred, suggesting the patent's strength and validity remain intact.
Q5: How does this patent integrate into a broader patent portfolio?
A: It likely forms part of a strategic family targeting various jurisdictions and aspects of the compound, including second-generation derivatives and expanded therapeutic uses.
References
[1] United States Patent and Trademark Office. Patent No. 8,236,282. August 7, 2012.
[2] Patent family documentation and related filings.
[3] Industry analyses on heterocyclic compounds and pharmaceutical patent strategies.
